Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE-backed CardioDx shoots for $86m IPO

This article was originally published in Clinica

Executive Summary

Another medtech firm is looking to capitalize on the currently favorable conditions in the public markets to raise some cash. CardioDx, a portfolio company of GE Healthcare that is developing noninvasive gene expression tests to help doctors better assess and treat patients with cardiovascular diseases, is looking to raise up to $86.3m in its IPO. It did not disclose how many shares it hopes to sell or at what price. If successful, it will list on the Nasdaq under the ticker symbol CDX.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT100966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel